CD8A and neoplasm: In addition, CXCL9, a ligand of CXCR3 that promotes adhesion to vascular endothelium for CXCR3, promotes the release of IFN-ɤ from CD8-positive T cells in the tumor by anti-VEGF antibody and anti-PD-1 antibody [37].